Drugs that delay cardiac repolarization pose potential safety risks to patients and cause serious regulatory concern because of the link between QT interval prolongation and the potentially fatal arrhythmia torsades de pointes (TdP).
HESI Cardiovascular Safety Subcommittee Initiative: Evaluation of Three Non-Clinical Models of QT Prolongation
Journal of Pharmacological and Toxicological Methods, 2006